Vertex Pharmaceuticals (VRTX) Change in Cash (2009 - 2026)

Vertex Pharmaceuticals has reported Change in Cash for 18 years, with the latest figure at $649.2 million in Q2 2026.

• On a quarterly basis, Change in Cash rose 118.88% year-over-year to $649.2 million in Q2 2026; TTM through Jun 2026 was $1.2 billion, a 199.77% increase from a year earlier, with the FY2025 full-year figure at $515.6 million, up 108.89% from the prior year.
• Change in Cash was $649.2 million for Q2 2026 at Vertex Pharmaceuticals, up from $417.1 million in the prior quarter.
• The five-year high for Change in Cash was $1.3 billion in Q4 2022, with the low at -$4.6 billion in Q2 2024.
• Average Change in Cash over 5 years is -$35.9 million, with a median of $356.8 million recorded in 2025.
• The sharpest annual moves came in 2022 and 2024: Change in Cash soared 554.96% in 2022, then plunged 633.74% in 2024.
• Over 5 years, Change in Cash stood at $1.3 billion in 2022, then sank by 155.75% to -$744.3 million in 2023, then climbed by 9.19% to -$675.9 million in 2024, then soared by 120.71% to $140.0 million in 2025, then jumped by 363.71% to $649.2 million in 2026.
• The last three Change in Cash figures came in at $649.2 million (Q2 2026), $417.1 million (Q1 2026), and $140.0 million (Q4 2025), per Business Quant data.